These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 23949011)
1. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells. Lee WH; Liu HE; Chang JY; Liou JP; Huang HM Pharmacology; 2013; 92(1-2):90-8. PubMed ID: 23949011 [TBL] [Abstract][Full Text] [Related]
2. MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation. Wang CC; Liu HE; Lee YL; Huang YW; Chen YJ; Liou JP; Huang HM Tumour Biol; 2016 May; 37(5):6065-72. PubMed ID: 26608370 [TBL] [Abstract][Full Text] [Related]
3. MPT0B169 and MPT0B002, New Tubulin Inhibitors, Induce Growth Inhibition, G2/M Cell Cycle Arrest, and Apoptosis in Human Colorectal Cancer Cells. Lee CH; Lin YF; Chen YC; Wong SM; Juan SH; Huang HM Pharmacology; 2018; 102(5-6):262-271. PubMed ID: 30227438 [TBL] [Abstract][Full Text] [Related]
4. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells. Wong SM; Liu FH; Lee YL; Huang HM PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740 [TBL] [Abstract][Full Text] [Related]
5. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383 [TBL] [Abstract][Full Text] [Related]
6. Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways. Chen YC; Lu PH; Pan SL; Teng CM; Kuo SC; Lin TP; Ho YF; Huang YC; Guh JH Biochem Pharmacol; 2007 Jun; 74(1):10-9. PubMed ID: 17475221 [TBL] [Abstract][Full Text] [Related]
7. 2-(Naphthalene-1-yl)-6-pyrrolidinyl-4-quinazolinone inhibits skin cancer M21 cell proliferation through aberrant expression of microtubules and the cell cycle. Wu YC; Hour MJ; Leung WC; Wu CY; Liu WZ; Chang YH; Lee HZ J Pharmacol Exp Ther; 2011 Sep; 338(3):942-51. PubMed ID: 21652781 [TBL] [Abstract][Full Text] [Related]
8. MJ-29 inhibits tubulin polymerization, induces mitotic arrest, and triggers apoptosis via cyclin-dependent kinase 1-mediated Bcl-2 phosphorylation in human leukemia U937 cells. Yang JS; Hour MJ; Huang WW; Lin KL; Kuo SC; Chung JG J Pharmacol Exp Ther; 2010 Aug; 334(2):477-88. PubMed ID: 20463006 [TBL] [Abstract][Full Text] [Related]
9. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695 [TBL] [Abstract][Full Text] [Related]
10. Identification of tubulin as the molecular target of proapoptotic pyrrolo-1,5-benzoxazepines. Mulligan JM; Greene LM; Cloonan S; Mc Gee MM; Onnis V; Campiani G; Fattorusso C; Lawler M; Williams DC; Zisterer DM Mol Pharmacol; 2006 Jul; 70(1):60-70. PubMed ID: 16571652 [TBL] [Abstract][Full Text] [Related]
11. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674 [TBL] [Abstract][Full Text] [Related]
12. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Dong XL; Xu PF; Miao C; Fu ZY; Li QP; Tang PY; Wang T Biomed Pharmacother; 2012 Feb; 66(1):70-5. PubMed ID: 22264882 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel 2-N-aryl-substituted benzenesulfonamidoacetamides: orally bioavailable tubulin polymerization inhibitors with marked antitumor activities. Liu Z; Zhou Z; Tian W; Fan X; Xue D; Yu L; Yu Q; Long YQ ChemMedChem; 2012 Apr; 7(4):680-93. PubMed ID: 22311585 [TBL] [Abstract][Full Text] [Related]
14. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells. Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672 [TBL] [Abstract][Full Text] [Related]
15. 10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization. Prinz H; Schmidt P; Böhm KJ; Baasner S; Müller K; Unger E; Gerlach M; Günther EG J Med Chem; 2009 Mar; 52(5):1284-94. PubMed ID: 19220018 [TBL] [Abstract][Full Text] [Related]
16. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Zhang LH; Wu L; Raymon HK; Chen RS; Corral L; Shirley MA; Narla RK; Gamez J; Muller GW; Stirling DI; Bartlett JB; Schafer PH; Payvandi F Cancer Res; 2006 Jan; 66(2):951-9. PubMed ID: 16424030 [TBL] [Abstract][Full Text] [Related]
17. Methyl 5-[(1H-indol-3-yl)selanyl]-1H-benzoimidazol-2-ylcarbamate (M-24), a novel tubulin inhibitor, causes G2/M arrest and cell apoptosis by disrupting tubulin polymerization in human cervical and breast cancer cells. Zuo D; Jiang X; Han M; Shen J; Lang B; Guan Q; Bai Z; Han C; Li Z; Zhang W; Wu Y Toxicol In Vitro; 2017 Aug; 42():139-149. PubMed ID: 28412508 [TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines. Králová V; Hanušová V; Staňková P; Knoppová K; Čáňová K; Skálová L Anticancer Drugs; 2013 Oct; 24(9):911-9. PubMed ID: 23884106 [TBL] [Abstract][Full Text] [Related]
19. Structure-based virtual screening of novel tubulin inhibitors and their characterization as anti-mitotic agents. Kim ND; Park ES; Kim YH; Moon SK; Lee SS; Ahn SK; Yu DY; No KT; Kim KH Bioorg Med Chem; 2010 Oct; 18(19):7092-100. PubMed ID: 20810285 [TBL] [Abstract][Full Text] [Related]
20. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]